The kallikrein-kinin system: Current and future pharmacological targets

Journal of Pharmacological Sciences

Volumn 99, Issue 1, 2005, Pages 6-38

  Moreau, Marie Eve ^a   Garbacki, Nancy ^b   Molinaro, Giuseppe ^a   Brown, Nancy J ^c   Marceau, François ^d   Adam, Albert ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c VANDERBILT UNIVERSITY   (United States)

^d LAVAL UNIVERSITY   (Canada)

Author keywords

B1 and B2 receptors; Kallikrein kinin system; Metallopeptidase; Pharmacological agent

Indexed keywords

3 (6 ACETAMIDO 3 PYRIDYL) N [N [2,4 DICHLORO 3 [(2 METHYL 8 QUINOLINYL)OXYMETHYL]PHENYL] N METHYLAMINOCARBONYLMETHYL]ACRYLAMIDE; 3 BROMO 8 [2,6 DICHLORO 3 [N [4 (N,N DIMETHYLCARBAMOYL)CINNAMIDOACETYL] N METHYLAMINO]BENZYLOXY] 2 METHYLIMIDAZO[1,2 A]PYRIDINE; 8 [2,6 DICHLORO 3 [N [4 (N METHYLCARBAMOYL)CINNAMAMIDOACETYL] N METHYLAMINO]BENZYLOXY] 2 METHYLQUINOLINE; AMINOPEPTIDASE; ANGIOTENSINASE; ANTIFIBRINOLYTIC AGENT; BERINERT; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CAPTOPRIL; COMPLEMENT COMPONENT C1S INHIBITOR; CP 0597; CP 2522; CYKLO F; DANAZOL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DX 88; FR 184280; HIGH MOLECULAR WEIGHT KININOGEN; ICATIBANT; KALLIKREIN; KALLIKREIN INHIBITOR; KININ; LISINOPRIL; LOW MOLECULAR WEIGHT KININOGEN; MEMBRANE METALLOENDOPEPTIDASE; PLASMA KININ; PREKALLIKREIN; PS 020990; SERINE PROTEINASE INHIBITOR; STANOZOLOL; TRANEXAMIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; WIN 62318; [[4 [2 [[BIS(CYCLOHEXYLAMINO)METHYLENE]AMINO] 3 (2 NAPHTHYL)PROPIONAMIDO] PHENYL]METHYL]TRIBUTYLPHOSPHONIUM CHLORIDE; [[4 [2 [[BIS(CYCLOHEXYLAMINO)METHYLENE]AMINO] 3 (2 NAPHTHYL)PROPIONAMIDO]PHENYL]METHYL]TRIBUTYLPHOSPHONIUM CHLORIDE;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DNA POLYMORPHISM; DRUG ACTIVITY; DRUG BINDING; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME REGULATION; ENZYME SYNTHESIS; EXON; GENE DELETION; GENE INSERTION; GENE LOCATION; HUMAN; INFLAMMATION; KALLIKREIN KININ SYSTEM; KIDNEY DISEASE; NEUROLOGIC DISEASE; NONHUMAN; PAIN; PROTEIN FUNCTION; RESPIRATORY TRACT DISEASE; REVIEW; SEPSIS; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION;

EID: 25444504534     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.SRJ05001X     Document Type: Review

References (329)

1. Abelous J, Bardier E. Les substances hypotensives de l'urine humaine normale. CR Soc Biol. 1909;66:511-512. (in French)
2. Sakamoto W, Satoh F, Gotoh K, Uehara S. Ile-Ser-bradykinin (T-kinin) and Met-Ile-Ser-bradykinin (Met-T-kinin) are released from T-kininogen by an acid proteinase of granulomatous tissues in rats. FEBS Lett. 1987;219:437-440.
3. Takagaki Y, Kitamura N, Nakanishi S. Cloning and sequence analysis of cDNAs for human high molecular weight and low molecular weight prekininogens. Primary structures of two human prekininogens. J Biol Chem. 1985;260:8601-8609.
4. Kitamura N, Kitagawa H, Fukushima D, Takagaki Y, Miyata T, Nakanishi S. Structural organization of the human kininogen gene and a model for its evolution. J Biol Chem. 1985;260:8610-8617.
5. Adam A, Albert A, Calay G, Closset J, Damas J, Franchimont P. Human kininogens of low and high molecular mass: quantification by radioimmunoassay and determination of reference values. Clin Chem. 1985;31:423-426.
6. Higashiyama S, Ohkubo I, Ishiguro H, Sasaki M, Matsuda T, Nakamura R. Heavy chain of human high molecular weight and low molecular weight kininogens binds calcium ion. Biochemistry. 1987;26:7450-7458.
7. Salvesen G, Parkes C, Abrahamson M, Grubb A, Barrett AJ. Human low-Mr kininogen contains three copies of a cystatin sequence that are divergent in structure and in inhibitory activity for cysteine proteinases. Biochem J. 1986;234:429-434.
8. Jiang YP, Muller-Esterl W, Schmaier AH. Domain 3 of kininogens contains a cell-binding site and a site that modifies thrombin activation of platelets. J Biol Chem. 1992;267:3712-3717.
9. Hasan AA, Cines DB, Ngaiza JR, Jaffe EA, Schmaier AH. Highmolecular-weight kininogen is exclusively membrane bound on endothelial cells to influence activation of vascular endothelium. Blood. 1995;85:3134-3143.
10. Colman RW, Jameson BA, Lin Y, Johnson D, Mousa SA. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood. 2000;95:543-550.
11. Lin Y, Pixley RA, Colman RW. Kinetic analysis of the role of zinc in the interaction of domain 5 of high-molecular weight kininogen (HK) with heparin. Biochemistry. 2000;39:5104-5110.
12. Tait JF, Fujikawa K. Primary structure requirements for the binding of human high molecular weight kininogen to plasma prekallikrein and factor XI. J Biol Chem. 1987;262:11651-11656.
13. Silverberg M, Nicoll JE, Kaplan AP. The mechanism by which the light chain of cleaved HMW-kininogen augments the activation of prekallikrein, factor XI and Hageman factor. Thromb Res. 1980;20:173-189.
14. Muller-Esterl W, Vohle-Timmermann M, Boos B, Dittman B. Purification and properties of human low molecular weight kininogen. Biochim Biophys Acta. 1982;706:145-152.
15. Beaubien G, Rosinski-Chupin I, Mattei MG, Mbikay M, Chretien M, Seidah NG. Gene structure and chromosomal localization of plasma kallikrein. Biochemistry. 1991;30:1628-1635.
16. Mandle RJ, Colman RW, Kaplan AP. Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma. Proc Natl Acad Sci U S A. 1976;73:4179-4183.
17. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev. 1992;44:1-80.
18. Reddigari S, Kaplan AP. Quantification of human high molecular weight kininogen by immunoblotting with a monoclonal anti-light chain antibody. J Immunol Methods. 1989;119:19-25.
19. Kaplan AP, Joseph K, Shibayama Y, Reddigari S, Ghebrehiwet B, Silverberg M. The intrinsic coagulation/kinin-forming cascade: assembly in plasma and cell surfaces in inflammation. Adv Immunol. 1997;66:225-272.
20. Merlini PA, Cugno M, Rossi ML, et al. Activation of the contact system and inflammation after thrombolytic therapy in patients with acute myocardial infarction. Am J Cardiol. 2004;93:822-825.
21. Kaplan AP, Joseph K, Silverberg M. Pathways for bradykinin formation and inflammatory disease. J Allergy Clin Immunol. 2002;109:195-209.
22. Kaplan AP, Silverberg M. The coagulation-kinin pathway of human plasma. Blood. 1987;70:1-15.
23. Mori K, Sakamoto W, Nagasawa S. Studies on human high molecular weight (HMW) kininogen. III. Cleavage of HMW kininogen by the action of human salivary kallikrein. J Biochem (Tokyo). 1981;90:503-509.
24. Guo YL, Colman RW. Two faces of high-molecular-weight kininogen (HK) in angiogenesis: bradykinin turns it on and cleaved HK (HKa) turns it off. J Thromb Haemost. 2005;3:670-676.
25. Zhao Y, Qiu Q, Mahdi F, Shariat-Madar Z, Rojkjaer R, Schmaier AH. Assembly and activation of HK-PK complex on endothelial cells results in bradykinin liberation and NO formation. Am J Physiol Heart Circ Physiol. 2001;280:H1821-1829.
26. Schmaier AH, Kuo A, Lundberg D, Murray S, Cines DB. The expression of high molecular weight kininogen on human umbilical vein endothelial cells. J Biol Chem. 1988;263:16327-16333.
27. van Iwaarden F, de Groot PG, Bouma BN. The binding of high molecular weight kininogen to cultured human endothelial cells. J Biol Chem. 1988;263:4698-4703.
28. Reddigari SR, Kuna P, Miragliotta G, Shibayama Y, Nishikawa K, Kaplan AP. Human high molecular weight kininogen binds to human umbilical vein endothelial cells via its heavy and light chains. Blood. 1993;81:1306-1311.
29. Hasan AA, Cines DB, Herwald H, Schmaier AH, Muller-Esterl W. Mapping the cell binding site on high molecular weight kininogen domain 5. J Biol Chem. 1995;270:19256-19261.
30. Herwald H, Hasan AA, Godovac-Zimmermann J, Schmaier AH, Muller-Esterl W. Identification of an endothelial cell binding site on kininogen domain D3. J Biol Chem. 1995;270:14634-14642.
31. Motta G, Rojkjaer R, Hasan AA, Cines DB, Schmaier AH. High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: a novel mechanism for contact activation. Blood. 1998;91:516-528.
32. Nishikawa K, Shibayama Y, Kuna P, Calcaterra E, Kaplan AP, Reddigari SR. Generation of vasoactive peptide bradykinin from human umbilical vein endothelium-bound high molecular weight kininogen by plasma kallikrein. Blood. 1992;80:1980-1988.
33. Hasan AA, Zisman T, Schmaier AH. Identification of cytokeratin 1 as a binding protein and presentation receptor for kininogens on endothelial cells. Proc Natl Acad Sci U S A. 1998;95:3615-3620.
34. Shariat-Madar Z, Mahdi F, Schmaier AH. Mapping binding domains of kininogens on endothelial cell cytokeratin 1. J Biol Chem. 1999;274:7137-7145.
35. Herwald H, Dedio J, Kellner R, Loos M, Muller-Esterl W. Isolation and characterization of the kininogen-binding protein p33 from endothelial cells. Identity with the gC1q receptor. J Biol Chem. 1996;271:13040-13047.
36. Joseph K, Ghebrehiwet B, Peerschke EI, Reid KB, Kaplan AP. Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: identity with the receptor that binds to the globular "heads" of C1q (gC1q-R). Proc Natl Acad Sci U S A. 1996;93:8552-8557.
37. Colman RW, Pixley RA, Najamunnisa S, Yan W, Wang J, Mazar A, et al. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor. J Clin Invest. 1997;100:1481-1487.
38. Schmaier AH. Plasma kallikrein/kinin system: a revised hypothesis for its activation and its physiologic contributions. Curr Opin Hematol. 2000;7:261-265.
39. Mahdi F, Shariat-Madar Z, Todd RF, 3rd, Figueroa CD, Schmaier AH. Expression and colocalization of cytokeratin 1 and urokinase plasminogen activator receptor on endothelial cells. Blood. 2001;97:2342-2350.
40. Mahdi F, Madar ZS, Figueroa CD, Schmaier AH. Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial cell membranes. Blood. 2002;99:3585-3596.
41. Clements J, Hooper J, Dong Y, Harvey T. The expanded human kallikrein (KLK) gene family: genomic organisation, tissue-specific expression and potential functions. Biol Chem. 2001;382:5-14.
42. Mahabeer R, Bhoola KD. Kallikrein and kinin receptor genes. Pharmacol Ther. 2000;88:77-89.
43. Marcondes S, Antunes E. The plasma and tissue kininogen-kallikrein-kinin system: role in the cardiovascular system. Curr Med Chem Cardiovasc Hematol Agents. 2005;3:33-44.
44. Kaplan AP, Joseph K, Shibayama Y, Nakazawa Y, Ghebrehiwet B, Reddigari S, et al. Bradykinin formation. Plasma and tissue pathways and cellular interactions. Clin Rev Allergy Immunol. 1998;16:403-429.
45. Fogaca SE, Melo RL, Pimenta DC, Hosoi K, Juliano L, Juliano MA. Differences in substrate and inhibitor sequence specificity of human, mouse and rat tissue kallikreins. Biochem J. 2004;380:775-781.
46. Dobrovolsky AB, Titaeva EV. The fibrinolysis system: regulation of activity and physiologic functions of its main components. Biochemistry (Mosc). 2002;67:99-108.
47. Molinaro G, Gervais N, Adam A. Biochemical basis of angioedema associated with recombinant tissue plasminogen activator treatment: an in vitro experimental approach. Stroke. 2002;33:1712-1716.
48. Norris LA. Blood coagulation. Best Pract Res Clin Obstet Gynaecol. 2003;17:369-383.
49. Breen P. Basics of coagulation pathways. Int Anesthesiol Clin. 2004;42:1-9.
50. Pixley RA, Schapira M, Colman RW. The regulation of human factor XIIa by plasma proteinase inhibitors. J Biol Chem. 1985;260:1723-1729.
51. Cugno M, Hack CE, de Boer JP, Eerenberg AJ, Agostoni A, Cicardi M. Generation of plasmin during acute attacks of hereditary angioedema. J Lab Clin Med. 1993;121:38-43.
52. Chai KX, Chen VC, Ni A, Lindpainther K, Rubattu S, Chao L, et al. Molecular cloning and expression of rat kallistatin gene. Biochim Biophys Acta. 1997;1353:277-286.
53. Chao J, Miao RQ, Chen V, Chen LM, Chao L. Novel roles of kallistatin, a specific tissue kallikrein inhibitor, in vascular remodeling. Biol Chem. 2001;382:15-21.
54. Emeis JJ, Kooistra T. Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med. 1986;163:1260-1266.
55. Erdös E, Skidgel R. Metabolism of bradykinin by peptidases in health and disease. In: Farmer S, ed. The kinin system. San Diego: Academic Press; 1997. p. 111-141.
56. Turner AJ, Hooper NM. The angiotensin-converting enzyme gene family: genomics and pharmacology. Trends Pharmacol Sci. 2002;23:177-183.
57. Hagaman JR, Moyer JS, Bachman ES, Sibony M, Magyar PL, Welch JE, et al. Angiotensin-converting enzyme and male fertility. Proc Natl Acad Sci U S A. 1998;95:2552-2557.
58. Georgiadis D, Beau F, Czarny B, Cotton J, Yiotakis A, Dive V. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors. Circ Res. 2003;93:148-154.
59. Soubrier F, Alhenc-Gelas F, Hubert C, Allegrini J, John M, Tregear G, et al. Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc Natl Acad Sci U S A. 1988;85:9386-9390.
60. Andujar-Sanchez M, Camara-Artigas A, Jara-Perez V. A calorimetric study of the binding of lisinopril, enalaprilat and captopril to angiotensin- converting enzyme. Biophys Chem. 2004;111:183-189.
61. Hooper NM, Turner AJ. An ACE structure. Nat Struct Biol. 2003;10:155-157.
62. Ehlers MR, Fox EA, Strydom DJ, Riordan JF. Molecular cloning of human testicular angiotensin-converting enzyme: the testis isozyme is identical to the C-terminal half of endothelial angiotensin-converting enzyme. Proc Natl Acad Sci U S A. 1989;86:7741-7745.
63. Oppong SY, Hooper NM. Characterization of a secretase activity which releases angiotensin-converting enzyme from the membrane. Biochem J. 1993;292:597-603.
64. Allinson TM, Parkin ET, Condon TP, Schwager SL, Sturrock ED, Turner AJ, et al. The role of ADAM10 and ADAM17 in the ectodomain shedding of angiotensin converting enzyme and the amyloid precursor protein. Eur J Biochem. 2004;271:2539-2547.
65. Parkin ET, Trew A, Christie G, Faller A, Mayer R, Turner AJ, et al. Structure-activity relationship of hydroxamate-based inhibitors on the secretases that cleave the amyloid precursor protein, angiotensin converting enzyme, CD23, and pro-tumor necrosis factor-alpha. Biochemistry. 2002;41:4972-4981.
66. Igic R, Behnia R. Properties and distribution of angiotensin I converting enzyme. Curr Pharm Des. 2003;9:697-706.
67. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Staglinano N, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87:E1-E9.
68. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase (ACE2). J Biol Chem. 2002;28:28.
69. Tian XL, Pinto YM, Costerousse O, Franz WM, Lippolat A, Hoffman S, et al. Over-expression of angiotensin converting enzyme-1 augments cardiac hypertrophy in transgenic rats. Hum Mol Genet. 2004;13:1441-1450.
70. Itoyama S, Keicho N, Quy T, Phi NC, Long HT, Ha le D, et al. ACE1 polymorphism and progression of SARS. Biochem Biophys Res Commun. 2004;323:1124-1129.
71. Hubert C, Houot AM, Corvol P, Soubrier F. Structure of the angiotensin I-converting enzyme gene. Two alternate promoters correspond to evolutionary steps of a duplicated gene. J Biol Chem. 1991;266:15377-15383.
72. Blais C Jr, Marceau F, Rouleau JL, Adam A. The kallikreinkininogen-kinin system: lessons from the quantification of endogenous kinins. Peptides. 2000;21:1903-1940.
73. Erdos EG. Some old and some new ideas on kinin metabolism. J Cardiovasc Pharmacol. 1990;15:S20-S24.
74. Inokuchi J, Nagamatsu A. Tripeptidyl carboxypeptidase activity of kininase II (angiotensin-converting enzyme). Biochim Biophys Acta. 1981;662:300-307.
75. Oshima G, Hiraga Y, Shirono K, Oh-ishi S, Sakakibara S, Kinoshita T. Cleavage of des-Arg9-bradykinin by angiotensin I-converting enzyme from pig kidney cortex. Experientia. 1985;41:325-328.
76. Kondoh G, Tojo H, Nakatani Y, Komazawa N, Murata C, Yamagata K, et al. Angiotensin-converting enzyme is a GPI-anchored protein releasing factor crucial for fertilization. Nat Med. 2005;11:160-166.
77. Tsujioka H, Misumi Y, Takami N, Ikehara Y. Posttranslational modification of glycosylphosphatidylinositol (GPI)-specific phospholipase D and its activity in cleavage of GPI anchors. Biochem Biophys Res Commun. 1998;251:737-743.
78. Kohlstedt K, Shoghi F, Muller-Esterl W, Busse R, Fleming I. CK2 phosphorylates the angiotensin-converting enzyme and regulates its retention in the endothelial cell plasma membrane. Circ Res. 2002;91:749-756
79. Kohlstedt K, Brandes RP, Muller-Esterl W, Busse R, Fleming I. Angiotensin-converting enzyme is involved in outside-in signaling in endothelial cells. Circ Res. 2004;94:60-67.
80. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86:1343-1346.
81. Danser AH, Schunkert H. Renin-angiotensin system gene polymorphisms: potential mechanisms for their association with cardiovascular diseases. Eur J Pharmacol. 2000;410:303-316.
82. Brown NJ, Blais C Jr, Gandhi SK, Adam A. ACE insertion/deletion genotype affects bradykinin metabolism. J Cardiovasc Pharmacol. 1998;32:373-377.
83. Mattu RK, Needham EW, Galton DJ, Frangos E, Clark AJ, Caulfield M. A DNA variant at the angiotensin-converting enzyme gene locus associates with coronary artery disease in the Caerphilly Heart Study. Circulation. 1995;91:270-274.
84. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, et al. Deletion polymorphism in the gene for angiotensinconverting enzyme is a potent risk factor for myocardial infarction. Nature. 1992;359:641-644.
85. Kolsch H, Jessen F, Freymann N, Kreis M, Hentschel F, Maier W, et al. ACE I/D polymorphism is a risk factor of Alzheimer's disease but not of vascular dementia. Neurosci Lett. 2005;377:37-39.
86. Schunkert H, Hense HW, Holmer SR, Stender M, Perz S, Keil U, et al. Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. N Engl J Med. 1994;330:1634-1638.
87. Marre M, Jeunemaitre X, Gallois Y, Rodier M, Chatellier G, Sert C, et al. Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group. J Clin Invest. 1997;99:1585-1595.
88. Hooper NM. Families of zinc metalloproteases. FEBS Lett. 1994;354:1-6.
89. Turner AJ, Isaac RE, Coates D. The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function. Bioessays. 2001;23:261-269.
90. Turner AJ, Tanzawa K. Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. Faseb J. 1997;11:355-364.
91. Bonvouloir N, Lemieux N, Crine P, Boileau G, DesGroseillers L. Molecular cloning, tissue distribution, and chromosomal localization of MMEL2, a gene coding for a novel human member of the neutral endopeptidase-24.11 family. DNA Cell Biol. 2001;20:493-498.
92. Barker PE, Shipp MA, D'Adamio L, Masteller EL, Reinherz EL. The common acute lymphoblastic leukemia antigen gene maps to chromosomal region 3 (q21 - q27). J Immunol. 1989;142:283-287.
93. Kerr MA, Kenny AJ. The purification and specificity of a neutral endopeptidase from rabbit kidney brush border. Biochem J. 1974;137:477-488.
94. Gafford JT, Skidgel RA, Erdos EG, Hersh LB. Human kidney "enkephalinase", a neutral metalloendopeptidase that cleaves active peptides. Biochemistry. 1983;22:3265-3271.
95. Decarie A, Raymond P, Gervais N, Couture R, Adam A. Serum interspecies differences in metabolic pathways of bradykinin and [des-Arg9]BK: influence of enalaprilat. Am J Physiol. 1996;271:H1340-H1347.
96. Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, et al. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med. 2000;6:143-150.
97. Kanazawa M, Casley DJ, Sybertz EJ, Haslanger MF, Johnston CI. Localization and characterization of neutral metalloendopeptidase (EC 3.4.24.11), the degradative enzyme for atrial natriuretic peptide, in rat kidney using a radioiodinated neutral metalloendopeptidase inhibitor. J Pharmacol Exp Ther. 1992;261:1231-1237.
98. Rawlings ND, Barrett AJ. MEROPS: the peptidase database. Nucleic Acids Res. 2000;28:323-325.
99. Cottrell GS, Hooper NM, Turner AJ. Cloning, expression, and characterization of human cytosolic aminopeptidase P: a single manganese (II)-dependent enzyme. Biochemistry. 2000;39:15121-15128.
100. Venema RC, Ju H, Zou R, Venema VJ, Ryan JW. Cloning and tissue distribution of human membrane-bound aminopeptidase P. Biochim Biophys Acta. 1997;1354:45-48.
101. Molinaro G, Carmona AK, Juliano MA, Juliano L, Malitsukaya E, Yessine MA, et al. Human recombinant membrane-bound aminopeptidase P: production of a soluble form and characterization using novel, internally quenched fluorescent substrates. Biochem J. 2005;385:389-397.
102. Molinaro G, Boileau G, Adam A. Aminopeptidase P and vasoactive peptides: from fundamental aspects to clinical interests. In: Hooper NM, Lendeckel U, eds. Aminopeptidases in biology and disease. London: Kluwer Academic/Plenum Publishers; 2004. p. 251-269.
103. Hooper NM, Hryszko J, Oppong SY, Turner AJ. Inhibition by converting enzyme inhibitors of pig kidney aminopeptidase P. Hypertension. 1992;19:281-285.
104. Ersahin C, Szpaderska AM, Orawski AT, Simmons WH. Aminopeptidase P isozyme expression in human tissues and peripheral blood mononuclear cell fractions. Arch Biochem Biophys. 2005;435:303-310.
105. Sprinkle TJ, Caldwell C, Ryan JW. Cloning, chromosomal sublocalization of the human soluble aminopeptidase P gene (XPNPEP1) to 10q25.3 and conservation of the putative proton shuttle and metal ligand binding sites with XPNPEP2. Arch Biochem Biophys. 2000;378:51-56.
106. Sprinkle TJ, Stone AA, Venema RC, Denslow ND, Caldwell C, Ryan JW. Assignment of the membrane-bound human amino-peptidase P gene (XPNPEP2) to chromosome Xq25. Genomics. 1998;50:114-116.
107. Hooper NM, Turner AJ. Ectoenzymes of the kidney microvillar membrane. Aminopeptidase P is anchored by a glycosyl-phosphatidylinositol moiety. FEBS Lett. 1988;229:340-344.
108. Ryan JW, Berryer P, Chung AY, Sheffy DH. Characterization of rat pulmonary vascular aminopeptidase P in vivo: role in the inactivation of bradykinin. J Pharmacol Exp Ther. 1994;269:941-947.
109. Prechel MM, Orawski AT, Maggiora LL, Simmons WH. Effect of a new aminopeptidase P inhibitor, apstatin, on bradykinin degradation in the rat lung. J Pharmacol Exp Ther. 1995;275:1136-1142.
110. Ersahin C, Simmons WH. Inhibition of both aminopeptidase P and angiotensin-converting enzyme prevents bradykinin degradation in the rat coronary circulation. J Cardiovasc Pharmacol. 1997;30:96-101.
111. Ryan JW, Papapetropoulos A, Ju H, Denslow ND, Antonov A, Virmani R, et al. Aminopeptidase P is disposed on human endothelial cells. Immunopharmacology. 1996;32:149-152.
112. Lasch J, Moschner S, Sann H, Zellmer S, Koelsch R. Aminopeptidase P - a cell-surface antigen of endothelial and lymphoid cells: catalytic and immuno-histotopical evidences. Biol Chem. 1998;379:705-709.
113. Harbeck HT, Mentlein R. Aminopeptidase P from rat brain. Purification and action on bioactive peptides. Eur J Biochem. 1991;198:451-458.
114. Rusu I, Yaron A. Aminopeptidase P from human leukocytes. Eur J Biochem. 1992;210:93-100.
115. Gilmartin L, O'Cuinn G. Dipeptidyl aminopeptidase IV and aminopeptidase P, two proline specific enzymes from the cytoplasm of guinea-pig brain: their role in metabolism of peptides containing consecutive prolines. Neurosci Res. 1999;34:1-11.
116. Simmons WH, Orawski AT. Membrane-bound aminopeptidase P from bovine lung. Its purification, properties, and degradation of bradykinin. J Biol Chem. 1992;267:4897-4903.
117. Orawski AT, Simmons WH. Purification and properties of membrane-bound aminopeptidase P from rat lung. Biochemistry. 1995;34:11227-11236.
118. Yoshimoto T, Orawski AT, Simmons WH. Substrate specificity of aminopeptidase P from Escherichia coli: comparison with membrane-bound forms from rat and bovine lung. Arch Biochem Biophys. 1994;311:28-34.
119. Blais C Jr, Marc-Aurele J, Simmons WH, Loute G, Thibault P, Skidgel RA, et al. Des-Arg9-bradykinin metabolism in patients who presented hypersensitivity reactions during hemodialysis: role of serum ACE and aminopeptidase P. Peptides. 1999;20:421-430.
120. Tan F, Chan SJ, Steiner DF, Schilling JW, Skidgel RA. Molecular cloning and sequencing of the cDNA for human membrane-bound carboxypeptidase M. Comparison with carboxypeptidases A, B, H, and N. J Biol Chem. 1989;264:13165-13170.
121. Skidgel RA. Basic carboxypeptidases: regulators of peptide hormone activity. Trends Pharmacol Sci. 1988;9:299-304.
122. Lambeir AM, Durinx C, Scharpe S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 2003;40:209-294.
123. Mentlein R. Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul Pept. 1999;85:9-24.
124. Olsen J, Kokholm K, Noren O, Sjostrom H. Structure and expression of aminopeptidase N. Adv Exp Med Biol. 1997;421:47-57.
125. Hoffmann T, Faust J, Neubert K, Ansorge S. Dipeptidyl peptidase IV (CD 26) and aminopeptidase N (CD 13) catalyzed hydrolysis of cytokines and peptides with N-terminal cytokine sequences. FEBS Lett. 1993;336:61-64.
126. Ward PE, Benter IF, Dick L, Wilk S. Metabolism of vasoactive peptides by plasma and purified renal aminopeptidase M. Biochem Pharmacol. 1990;40:1725-1732.
127. Pelorosso FG, Brodsky PT, Zold CL, Rothlin RP. Potentiation of des-Arg9-kallidin induced vasoconstrictor responses by metallo-peptidase inhibition in isolated human umbilical artery. J Pharmacol Exp Ther. 2005;313:1355-1360.
128. Drapeau G, deBlois D, Marceau F. Hypotensive effects of Lysdes-Arg9-bradykinin and metabolically protected agonists of B1 receptors for kinins. J Pharmacol Exp Ther. 1991;259:997-1003.
129. Leeb-Lundberg LM, Marceau F, Muller-Esterl W, Pettibone DJ, Zuraw BL. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev. 2005;57:27-77.
130. Marceau F, Hess JF, Bachvarov DR. The B1 receptors for kinins. Pharmacol Rev. 1998;50:357-386.
131. Babiuk C, Marceau F, St-Pierre S, Regoli D. Kininases and vascular responses to kinins. Eur J Pharmacol. 1982;78:167-174.
132. Regoli D, Barabe J, Park WK. Receptors for bradykinin in rabbit aortae. Can J Physiol Pharmacol. 1977;55:855-867.
133. Vavrek RJ, Stewart JM. Competitive antagonists of bradykinin. Peptides. 1985;6:161-164.
134. Hock FJ, Wirth K, Albus U, Linz W, Gerhards HJ, Wiemer G, et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol. 1991;102:769-773.
135. Houle S, Larrivee JF, Bachvarova M, Bouthillier J, Bachvarov DR, Marceau F. Antagonist-induced intracellular sequestration of rabbit bradykinin B(2) receptor. Hypertension. 2000;35:1319-1325.
136. Regoli D, Nsa Allogho S, Rizzi A, Gobeil FJ. Bradykinin receptors and their antagonists. Eur J Pharmacol. 1998;348:1-10.
137. Salvino JM, Seoane PR, Douty BD, Awad MM, Dolle RE, Houck WT, et al. Design of potent non-peptide competitive antagonists of the human bradykinin B2 receptor. J Med Chem. 1993;36:2583-2584.
138. Altamura M, Meini S, Quartara L, Maggi CA. Nonpeptide antagonists for kinin receptors. Regul Pept. 1999;80:13-26.
139. Horlick RA, Ohlmeyer MH, Stroke IL, Strohl B, Pan G, Schilling AE, et al. Small molecule antagonists of the bradykinin B1 receptor. Immunopharmacology. 1999;43:169-177.
140. Wood MR, Kim JJ, Han W, Dorsey BD, Homnick CF, DiPardo RM, et al. Benzodiazepines as potent and selective bradykinin B1 antagonists. J Med Chem. 2003;46:1803-1806.
141. Morissette G, Fortin JP, Otis S, Bouthillier J, Marceau F. A novel nonpeptide antagonist of the kinin B1 receptor: effects at the rabbit receptor. J Pharmacol Exp Ther. 2004;311:1121-1130.
142. Ritchie TJ, Dziadulewicz EK, Culshaw AJ, Muller W, Burgess GM, Bloomfield GC, et al. Potent and orally bioavailable nonpeptide antagonists at the human bradykinin B(1) receptor based on a 2-alkylamino-5-sulfamoylbenzamide core. J Med Chem. 2004;47:4642-4644.
143. Gougat J, Ferrari B, Sarran L, Planchenault C, Poncelet M, Maruani J, et al. SSR240612[(2R)-2-[((3R)-3-(1,3-benzodioxol-5-yl)-3-[[(6-methoxy-2-naphthyl) sulfonyl]amino]propanoyl) amino]-3-(4-[[2R,6S)-2,6-dimethylpiperidinyl]methyl] phenyl)-N-isopropyl-N-methylpropanamide hydrochloride], a new nonpeptide antagonist of the bradykinin B1 receptor: biochemical and pharmacological characterization. J Pharmacol Exp Ther. 2004;309:661-669.
144. Ma D, Xia C, Jiang J, Zhang J. First total synthesis of martinellic acid, a naturally occurring bradykinin receptor antagonist. Org Lett. 2001;3:2189-2191.
145. McEachern AE, Shelton ER, Bhakta S, Obernolte R, Bach C, Zuppan P, et al. Expression cloning of a rat B2 bradykinin receptor. Proc Natl Acad Sci U S A. 1991;88:7724-7728.
146. Menke JG, Borkowski JA, Bierilo KK, MacNeil T, Derrick AW, Schneck KA, et al. Expression cloning of a human B1 bradykinin receptor. J Biol Chem. 1994;269:21583-21586.
147. Bachvarov DR, Hess JF, Menke JG, Larrivee JF, Marceau F. Structure and genomic organization of the human B1 receptor gene for kinins (BDKRB1). Genomics. 1996;33:374-381.
148. Yang X, Polgar P. Genomic structure of the human bradykinin B1 receptor gene and preliminary characterization of its regulatory regions. Biochem Biophys Res Commun. 1996;222:718-725.
149. Leeb-Lundberg LM, Mathis SA, Herzig MC. Antagonists of bradykinin that stabilize a G-protein-uncoupled state of the B2 receptor act as inverse agonists in rat myometrial cells. J Biol Chem. 1994;269:25970-25973.
150. Fredriksson R, Lagerstrom MC, Lundin LG, Schioth HB. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol. 2003;63:1256-1272.
151. Couture R, Harrisson M, Vianna RM, Cloutier F. Kinin receptors in pain and inflammation. Eur J Pharmacol. 2001;429:161-176.
152. Kammerer S, Braun A, Arnold N, Roscher AA. The human bradykinin B2 receptor gene: full length cDNA, genomic organization and identification of the regulatory region. Biochem Biophys Res Commun. 1995;211:226-233.
153. Cayla C, Merino VF, Cabrini DA, Silva JA Jr, Pesquero JB, Bader M. Structure of the mammalian kinin receptor gene locus. Int Immunopharmacol. 2002;2:1721-1727.
154. Tschope C, Heringer-Walther S, Koch M, Spillmann F, Wandorf M, Leitner E, et al. Upregulation of bradykinin B1-receptor expression after myocardial infarction. Br J Pharmacol. 2000;129:1537-1538.
155. Phagoo SB, Yaqoob M, McIntyre P, Jones C, Burgess GM. Cytokines increase B1 bradykinin receptor mRNA and protein levels in human lung fibroblasts. Biochem Soc Trans. 1997;25:43S.
156. Zhou X, Polgar P, Taylor L. Roles for interleukin-1beta, phorbol ester and a post-transcriptional regulator in the control of bradykinin B1 receptor gene expression. Biochem J. 1998;330:361-366.
157. Phagoo SB, Yaqoob M, Herrera-Martinez E, McIntyre P, Jones C, Burgess GM. Regulation of bradykinin receptor gene expression in human lung fibroblasts. Eur J Pharmacol. 2000;397:237-246.
158. Davis AJ, Perkins MN. Induction of B1 receptors in vivo in a model of persistent inflammatory mechanical hyperalgesia in the rat. Neuropharmacology. 1994;33:127-133.
159. Larrivee JF, Bachvarov DR, Houle F, Landry J, Huot J, Marceau F. Role of the mitogen-activated protein kinases in the expression of the kinin B1 receptors induced by tissue injury. J Immunol. 1998;160:1419-1426.
160. Campos MM, Souza GE, Calixto JB. In vivo B1 kinin-receptor upregulation Evidence for involvement of protein kinases and nuclear factor kappaB pathways. Br J Pharmacol. 1999;127:1851-1859.
161. Ganju P, Davis A, Patel S, Nunez X, Fox A. p38 stress-activated protein kinase inhibitor reverses bradykinin B(1) receptor-mediated component of inflammatory hyperalgesia. Eur J Pharmacol. 2001;421:191-199.
162. Medeiros R, Cabrini DA, Ferreira J, Fernandes ES, Mori MA, Pesquero JB, et al. Bradykinin B1 receptor expression induced by tissue damage in the rat portal vein: a critical role for mitogen-activated protein kinase and nuclear factor-kappaB signaling pathways. Circ Res. 2004;94:1375-1382.
163. Sabourin T, Morissette G, Bouthillier J, Levesque L, Marceau F. Expression of kinin B(1) receptor in fresh or cultured rabbit aortic smooth muscle: role of NF-kappa B. Am J Physiol Heart Circ Physiol. 2002;283:H227-H237.
164. Sardi SP, Rey-Ares V, Pujol-Lereis VA, Serrano SA, Rothlin RP. Further pharmacological evidence of nuclear factor-kappaB pathway involvement in bradykinin B(1) receptor-sensitized responses in human umbilical vein. J Pharmacol Exp Ther. 2002;301:975-980.
165. Schanstra JP, Bataille E, Marin Castano ME, Barascud Y, Hirtz C, Pesquero JB, et al. The B1-agonist [des-Arg10]-kallidin activates transcription factor NF-kappaB and induces homologous upregulation of the bradykinin B1-receptor in cultured human lung fibroblasts. J Clin Invest. 1998;101:2080-2091.
166. Phagoo SB, Poole S, Leeb-Lundberg LM. Autoregulation of bradykinin receptors: agonists in the presence of interleukin-1beta shift the repertoire of receptor subtypes from B2 to B1 in human lung fibroblasts. Mol Pharmacol. 1999;56:325-333.
167. Bastian S, Paquet JL, Robert C, Cremers B, Loillier B, Larrivee JF, et al. Interleukin 8 (IL-8) induces the expression of kinin B1 receptor in human lung fibroblasts. Biochem Biophys Res Commun. 1998;253:750-755.
168. Sabourin T, Guay K, Houle S, Bouthillier J, Bachvarov PR, Adam A, et al. Absence of ligand-induced regulation of kinin receptor expression in the rabbit. Br J Pharmacol. 2001;133:1154-1162.
169. Yang X, Taylor L, Yu J, Fenton MJ, Polgar P. Mediator caused induction of a human bradykinin B1 receptor minigene: participation of c-Jun in the process. J Cell Biochem. 2001;82:163-170.
170. Pesquero JB, Lindsey CJ, Paiva AC, Ganten D, Bader M. Transcriptional regulatory elements in the rat bradykinin B2 receptor gene. Immunopharmacology. 1996;33:36-41.
171. Baptista HA, Avellar MC, Araujo RC, Pesquero JL, Schanstra JP, Bascands JL, et al. Transcriptional regulation of the rat bradykinin B2 receptor gene: identification of a silencer element. Mol Pharmacol. 2002;62:1344-1355.
172. Schmidlin F, Scherrer D, Daeffler L, Bertrand C, Landry Y, Gies JP. Interleukin-1beta induces bradykinin B2 receptor gene expression through a prostanoid cyclic AMP-dependent pathway in human bronchial smooth muscle cells. Mol Pharmacol. 1998;53:1009-1015.
173. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
174. Busse R, Fleming I. Molecular responses of endothelial tissue to kinins. Diabetes. 1996;45 Suppl 1:S8-S13.
175. Velarde V, Ullian ME, Morinelli TA, Mayfield RK, Jaffa AA. Mechanisms of MAPK activation by bradykinin in vascular smooth muscle cells. Am J Physiol. 1999;277:C253-C261.
176. Fleming I, Fisslthaler B, Busse R. Calcium signaling in endothelial cells involves activation of tyrosine kinases and leads to activation of mitogen-activated protein kinases. Circ Res. 1995;76:522-529.
177. Fleming I, Fisslthaler B, Busse R. Interdependence of calcium signaling and protein tyrosine phosphorylation in human endothelial cells. J Biol Chem. 1996;271:11009-11015.
178. Harris MB, Ju H, Venema VJ, Blackstone M, Venema RC. Role of heat shock protein 90 in bradykinin-stimulated endothelial nitric oxide release. Gen Pharmacol. 2000;35:165-170.
179. Marrero MB, Venema VJ, Ju H, He H, Liang H, Caldwell RB, et al. Endothelial nitric oxide synthase interactions with G-protein-coupled receptors. Biochem J. 1999;343 Pt 2:335-340.
180. Venema RC. Post-translational mechanisms of endothelial nitric oxide synthase regulation by bradykinin. Int Immunopharmacol. 2002;2:1755-1762.
181. Ju H, Venema VJ, Liang H, Harris MB, Zou R, Venema RC. Bradykinin activates the Janus-activated kinase/signal transducers and activators of transcription (JAK/STAT) pathway in vascular endothelial cells: localization of JAK/STAT signalling proteins in plasmalemmal caveolae. Biochem J. 2000;351:257-264.
182. Faussner A, Proud D, Towns M, Bathon JM. Influence of the cytosolic carboxyl termini of human B1 and B2 kinin receptors on receptor sequestration, ligand internalization, and signal transduction. J Biol Chem. 1998;273:2617-2623.
183. de Weerd WF, Leeb-Lundberg LM. Bradykinin sequesters B2 bradykinin receptors and the receptor-coupled Galpha subunits Galphaq and Galphai in caveolae in DDT1 MF-2 smooth muscle cells. J Biol Chem. 1997;272:17858-17866.
184. Blaukat A, Alla SA, Lohse MJ, Muller-Esterl W. Ligandinduced phosphorylation/dephosphorylation of the endogenous bradykinin B2 receptor from human fibroblasts. J Biol Chem. 1996;271:32366-32374.
185. Houle S, Molinaro G, Adam A, Marceau F. Tissue kallikrein actions at the rabbit natural or recombinant kinin B2 receptors. Hypertension. 2003;41:611-617.
186. Blaukat A, Pizard A, Rajerison RM, Alhenc-Gelas F, Muller-Esterl W, Dikic I. Activation of mitogen-activated protein kinase by the bradykinin B2 receptor is independent of receptor phosphorylation and phosphorylation-triggered internalization. FEBS Lett. 1999;451:337-341.
187. Sabourin T, Bastien L, Bachvarov DR, Marceau F. Agonist-induced translocation of the kinin B(1) receptor to caveolae-related rafts. Mol Pharmacol. 2002;61:546-553.
188. Colman RW, Wong PY. Participation of Hageman factor dependent pathways in human disease states. Thromb Haemost. 1977;38:751-775.
189. Braat EA, Dooijewaard G, Rijken DC. Fibrinolytic properties of activated FXII. Eur J Biochem. 1999;263:904-911.
190. Agostoni A, Aygoren-Pursun E, Binkley KE, Blanch A, Bork K, Bouillet L, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004;114:S51-S131.
191. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet. 1998;351:1693-1697.
192. Nussberger J, Cugno M, Cicardi M. Bradykinin-mediated angioedema. N Engl J Med. 2002;347:621-622.
193. Davis AE. The pathogenesis of hereditary angioedema. Transfus Apheresis Sci. 2003;29:195-203.
194. Cugno M, Nussberger J, Cicardi M, Agostoni A. Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol. 2003;3:311-317.
195. Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore). 1992;71:206-215.
196. Zuraw BL. Current and future therapy for hereditary angioedema. Clin Immunol. 2005;114:10-16.
197. Han ED, MacFarlane RC, Mulligan AN, Scafidi J, Davis AE 3rd. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest. 2002;109:1057-1063.
198. Bork K, Dewald G. Hereditary angioedema type III, angioedema associated with angiotensin II receptor antagonists, and female sex. Am J Med. 2004;116:644-645.
199. Engh RA, Huber R, Bode W, Schulze AJ. Divining the serpin inhibition mechanism: a suicide substrate 'springe'? Trends Biotechnol. 1995;13:503-510.
200. Alston TA. Aprotinin. Int Anesthesiol Clin. 2004;42:81-91.
201. Nagaya M, Futamura M, Kato J, Niimi N, Fukuta S. Application of a new anticoagulant (Nafamostat Mesilate) to control hemorrhagic complications during extracorporeal membrane oxygenation - a preliminary report. J Pediatr Surg. 1997;32:531-535.
202. Nakamura K, Onitsuka T, Yano M, Nagahama H, Nakamura E, Matsuzaki Y. Nafamostat mesilate treatment during open heart operation in immune thrombocytopenic purpura. Ann Thorac Surg. 2000;70:2161-2163.
203. De Serres J, Groner A, Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert((R)) P) in hereditary angioedema: a review. Transfus Apheresis Sci. 2003;29:247-254.
204. Han Lee ED, Pappalardo E, Scafidi J, Davis AE. Approaches toward reversal of increased vascular permeability in C1 inhibitor deficient mice. Immunol Lett. 2003;89:155-160.
205. Cicardi M, Zingale L. How do we treat patients with hereditary angioedema. Transfus Apheresis Sci. 2003;29:221-227.
206. Pappalardo E, Zingale LC, Cicardi M. Increased expression of C1-inhibitor mRNA in patients with hereditary angioedema treated with Danazol. Immunol Lett. 2003;86:271-276.
207. Wellington K, Wagstaff AJ. Tranexamic acid: a review of its use in the management of menorrhagia. Drugs. 2003;63:1417-1433.
208. Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs. 1999;57:1005-1032.
209. Rosenkrans B, Russmann S, Reichen J, Brunner-Ferber F, Bork K, Knolle J. Clinical proof-of-concept fort he bradykinin B2 antagonist; icatibant in liver cirrhosis and hereditary angioedema. Peptide Receptors Montreal 2004 Symposium. Montreal, Canada, 2004.
210. Mattsson E, Herwald H, Cramer H, Persson K, Sjobring U, Bjorck L. Staphylococcus aureus induces release of bradykinin in human plasma. Infect Immun. 2001;69:3877-3882.
211. Ueno A, Tokumasu T, Naraba H, Oh-ishi S. The mediators involved in endotoxin-induced vascular permeability increase in the rat skin and their interactions. Jpn J Pharmacol. 1996;70:285-290.
212. Shima C, Majima M, Katori M. A stable metabolite, Arg-Pro-Pro-Gly-Phe, of bradykinin in the degradation pathway in human plasma. Jpn J Pharmacol. 1992;60:111-119.
213. Morinelli TA, Webb JG, Jaffa AA, Privitera PJ, Margolius HS. A metabolic fragment of bradykinin, Arg-Pro-Pro-Gly-Phe, protects against the deleterious effects of lipopolysaccharide in rats. J Pharmacol Exp Ther. 2001;296:71-76.
214. Nieman MT, Warnock M, Hasan AA, Mahai F, Lucchesi BR, Brown NJ, et al. The preparation and characterization of novel peptide antagonists to thrombin and factor VIIa and activation of protease-activated receptor 1. J Pharmacol Exp Ther. 2004;311:492-501.
215. Verresen L, Waer M, Vanrenterghem Y, Michielsen P. Angiotensin- converting-enzyme inhibitors and anaphylactoid reactions to high-flux membrane dialysis. Lancet. 1990;336:1360-1362.
216. Cyr M, Eastlund T, Blais C Jr, Rouleau JL, Adam A. Bradykinin metabolism and hypotensive transfusion reactions. Transfusion. 2001;41:136-150.
217. Cugno M, Cicardi M, Agostoni A. Activation of the contact system and fibrinolysis in autoimmune acquired angioedema: a rationale for prophylactic use of tranexamic acid. J Allergy Clin Immunol. 1994;93:870-876.
218. Pretorius M, Rosenbaum D, Vaughan DE, Brown NJ. Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin. Circulation. 2003;107:579-585.
219. Soubrier F, Hubert C, Testut P, Nadaud S, Alhenc-Gelas F, Corvol P. Molecular biology of the angiotensin I converting enzyme: I. Biochemistry and structure of the gene. J Hypertens. 1993;11:471-476.
220. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417:822-828.
221. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation. 1996;94:258-265.
222. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
223. White HD. Should all patients with coronary disease receive angiotensin-converting-enzyme inhibitors? Lancet. 2003;362:755-757.
224. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669-677.
225. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995;333:1670-1676.
226. Borghi C, Bacchelli S, Degli Esposti D, Ambrosioni E. A review of the angiotensin-converting enzyme inhibitor, zofenopril, in the treatment of cardiovascular diseases. Expert Opin Pharmacother. 2004;5:1965-1977.
227. Lewis EJ. The treatment of hypertension in diabetic nephropathy. J Hum Hypertens. 1996;10:675-677.
228. Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Furberg CD. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care. 2000;23:888-892.
229. Boos CJ, Dawes M. ACE cardiovascular protection: EUROPA versus HOPE. Cardiovasc Drugs Ther. 2004;18:179-180.
230. Perez M, Molinaro G, Adam A. Bradykinin, an important mediator of the cardiovascular effects of metallopeptidase inhibitors: experimental and clinical evidences. J Clin Basic Cardiol. 2001;4:39-46.
231. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med. 1998;339:1285-1292.
232. Molinaro G, Rouleau JL, Adam A. Vasopeptidase inhibitors: a new class of dual zinc metallopeptidase inhibitors for cardiorenal therapeutics. Curr Opin Pharmacol. 2002;2:131-141.
233. Trippodo NC, Fox M, Monticello TM, Panchal BC, Asaad MM. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril. J Cardiovasc Pharmacol. 1999;34:782-790.
234. McClean DR, Ikram H, Garlick AH, Richards AM, Nicholls MG, Crozier IG. The clinical, cardiac, renal, arterial and neuro-hormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. J Am Coll Cardiol. 2000;36:479-486.
235. Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet. 2000;356:615-620.
236. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004;17:103-111.
237. Zanchi A, Maillard M, Burnier M. Recent clinical trials with omapatrilat: new developments. Curr Hypertens Rep. 2003;5:346-352.
238. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002;106:920-926.
239. Dumoulin MJ, Adam A, Rouleau JL, Lamontagne D. Comparison of a vasopeptidase inhibitor with neutral endopeptidase and angiotensin-converting enzyme inhibitors on bradykinin metabolism in the rat coronary bed. J Cardiovasc Pharmacol. 2001;37:359-366.
240. Raut R, Rouleau JL, Blais C Jr, Gosselin H, Molinaro G, Sirois MG, et al. Bradykinin metabolism in the postinfarcted rat heart: role of ACE and neutral endopeptidase 24.11. Am J Physiol. 1999;276:H1769-H1779.
241. Dumoulin MJ, Lamontagne D, Burnett J, Heublein D, Yamaguchi N, Adam A. Respective role of endogenous kinins and natriuretic peptides in the cardioprotective effect of omapatrilat following total heart ischemia (abstract). Eur Heart J. 2001;22:50.
242. Bralet J, Schwartz JC. Vasopeptidase inhibitors: an emerging class of cardiovascular drugs. Trends Pharmacol Sci. 2001;22:106-109.
243. Dumoulin MJ, Adam A, Burnett J, Heublein D, Yamaguchi N, Lamontagne D. The cardioprotective effect of dual metallopeptidase inhibition: respective roles of endogenous kinins and natriuretic peptides. Can J Physiol Pharmacol. 2005;83:166-173.
244. Hill MD, Barber PA, Takahashi J, Demchuk AM, Feasby TE, Buchan AM. Anaphylactoid reactions and angioedema during alteplase treatment of acute ischemic stroke. Cmaj. 2000;162:1281-1284.
245. Molinaro G, Adam A, Lepage Y, Hammerschmidt D, Koenigbauer U, Eastlund T. Hypotensive reaction during staphylococcal protein A column therapy in a patient with anomalous degradation of bradykinin and Des-Arg9-bradykinin after contact activation. Transfusion. 2002;42:1458-1465.
246. Coletta A, Thackray S, Nikitin N, Cleland JG. Clinical trials update: highlights of the scientific sessions of The American College of Cardiology 2002: LIFE, DANAMI 2, MADIT-2, MIRACLE-ICD, OVERTURE, OCTAVE, ENABLE 1 & 2, CHRISTMAS, AFFIRM, RACE, WIZARD, AZACS, REMATCH, BNP trial and HARDBALL. Eur J Heart Fail. 2002;4:381-388.
247. Adam A, Cugno M, Molinaro G, Perez M, Lepage Y, Agostoni A. Aminopeptidase P in individuals with a history of angiooedema on ACE inhibitors. Lancet. 2002;359:2088-2089.
248. Molinaro G, Cugno M, Perez M, Lepage Y, Gervais N, Agostoni A, et al. Angiotensin-converting enzyme Inhibitor-associated angioedema is characterized by a slower degradation of des-Arginine9-Bradykinin. J Pharmacol Exp Ther. 2002;303:232-237.
249. Arnold DM, Molinaro G, Warkentin TE, DiTomasso J, Webert KE, Davis I, et al. Hypotensive transfusion reactions can occur with blood products that are leukoreduced before storage. Transfusion. 2004;44:1361-1366.
250. Duan Q, Nikpoor B, Molinaro G, Meijer I, Rochefort D, Saint-Onge J, et al. Variants in XPNPEP2 increase susceptibility to ACE-inhibitor associated adverse reactions. Am J Hum Genet. In press 2005.
251. Lefebvre J, Murphey LJ, Hartert TV, Jiao Shan R, Simmons WH, Brown NJ. Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema. Hypertension. 2002;39:460-464.
252. Houle S, Landry M, Audet R, Bouthillier J, Bachvarov DR, Marceau F. Effect of allelic polymorphism of the B(1) and B(2) receptor genes on the contractile responses of the human umbilical vein to kinins. J Pharmacol Exp Ther. 2000;294:45-51.
253. Pe'er I, Beckmann JS. On the applicability of a haplotype map to un-assayed populations. Hum Genet. 2004;114:214-217.
254. Hess JF, Hey PJ, Chen TB, Pettibone DJ, Chang RS. Molecular and pharmacological diversity of the kinin B1 receptor. Int Immunopharmacol. 2002;2:1747-1754.
255. Brull D, Dhamrait S, Myerson S, Erdmann J, Woods D, World M, et al. Bradykinin B2BKR receptor polymorphism and left-ventricular growth response. Lancet. 2001;358:1155-1156.
256. Hallberg P, Lind L, Michaelsson K, Karlsson J, Kurland L, Kahan T, et al. B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. J Hypertens. 2003;21:621-624.
257. Williams AG, Dhamrait SS, Wootton PT, Day SH, Hawe E, Payne JR, et al. Bradykinin receptor gene variant and human physical performance. J Appl Physiol. 2004;96:938-942.
258. Dhamrait SS, Payne JR, Li P, Jones A, Toor IS, Cooper JA, et al. Variation in bradykinin receptor genes increases the cardiovascular risk associated with hypertension. Eur Heart J. 2003;24:1672-1680.
259. Maltais I, Bachvarova M, Maheux P, Perron P, Marceau F, Bachvarov D. Bradykinin B2 receptor gene polymorphism is associated with altered urinary albumin/creatinine values in diabetic patients. Can J Physiol Pharmacol. 2002;80:323-327.
260. Zee RY, Rao VS, Paster RZ, Sweet CS, Lindpaintner K. Three candidate genes and angiotensin-converting enzyme inhibitor-related cough: a pharmacogenetic analysis. Hypertension. 1998;31:925-928.
261. Cui J, Melista E, Chazaro I, Zhang Y, Zhou X, Manolis AJ, et al. Sequence variation of bradykinin receptors B1 and B2 and association with hypertension. J Hypertens. 2005;23:55-62.
262. Gainer JV, Brown NJ, Bachvarova M, Bastien L, Maltais I, Marceau F, et al. Altered frequency of a promoter polymorphism of the kinin B2 receptor gene in hypertensive African-Americans. Am J Hypertens. 2000;13:1268-1273.
263. Wang B, Dang A, Liu G. Genetic variation in the promoter region of the beta2 bradykinin receptor gene is associated with essential hypertension in a Chinese Han population. Hypertens Res. 2001;24:299-302.
264. Mukae S, Aoki S, Itoh S, Iwata T, Ueda H, Katagiri T. Bradykinin B(2) receptor gene polymorphism is associated with angiotensin-converting enzyme inhibitor-related cough. Hypertension. 2000;36:127-131.
265. Zychma MJ, Gumprecht J, Trautsolt W, Szydlowska I, Grzeszczak W. Polymorphic genes for kinin receptors, nephropathy and blood pressure in type 2 diabetic patients. Am J Nephrol. 2003;23:112-116.
266. Bachvarov DR, Landry M, Pelletier I, Chevrette M, Betard C, Houde I, et al. Characterization of two polymorphic sites in the human kinin B1 receptor gene: altered frequency of an allele in patients with a history of end-stage renal failure. J Am Soc Nephrol. 1998;9:598-604.
267. Bachvarov DR, Landry M, Houle S, Pare P, Marceau F. Altered frequency of a promoter polymorphic allele of the kinin B1 receptor gene in inflammatory bowel disease. Gastroenterology. 1998;115:1045-1048.
268. Ueno A, Oh-ishi S. Roles for the kallikrein-kinin system in inflammatory exudation and pain: lessons from studies on kininogen-deficient rats. J Pharmacol Sci. 2003;93:1-20.
269. Akbary AM, Wirth KJ, Scholkens BA. Efficacy and tolerability of Icatibant (Hoe 140) in patients with moderately severe chronic bronchial asthma. Immunopharmacology. 1996;33:238-242.
270. Turner P, Dear J, Scadding G, Foreman JC. Role of kinins in seasonal allergic rhinitis: icatibant, a bradykinin B2 receptor antagonist, abolishes the hyperresponsiveness and nasal eosinophilia induced by antigen. J Allergy Clin Immunol. 2001;107:105-113.
271. Proud D, Bathon JM, Togias AG, Naclerio RM. Inhibition of the response to nasal provocation with bradykinin by HOE-140: efficacy and duration of action. Can J Physiol Pharmacol. 1995;73:820-826.
272. Fein AM, Bernard GR, Criner GJ, Fletcher EC, Good JT Jr, Knaus WA, et al. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. Jama. 1997;277:482-487.
273. Heitsch H. The therapeutic potential of bradykinin B2 receptor agonists in the treatment of cardiovascular disease. Expert Opin Investig Drugs. 2003;12:759-770.
274. Groves P, Kurz S, Just H, Drexler H. Role of endogenous bradykinin in human coronary vasomotor control. Circulation. 1995;92:3424-3430.
275. Regoli DC, Marceau F, Lavigne J. Induction of beta 1-receptors for kinins in the rabbit by a bacterial lipopolysaccharide. Eur J Pharmacol. 1981;71:105-115.
276. deBlois D, Horlick RA. Endotoxin sensitization to kinin B(1) receptor agonist in a non-human primate model: haemodynamic and pro-inflammatory effects. Br J Pharmacol. 2001;132:327-335.
277. Ignarro LJ, Byrns RE, Buga GM, Wood KS. Mechanisms of endothelium-dependent vascular smooth muscle relaxation elicited by bradykinin and VIP. Am J Physiol. 1987;253:H1074-H1082.
278. Zhu P, Zaugg CE, Hornstein PS, Allegrini PR, Buser PT. Bradykinin-dependent cardioprotective effects of losartan against ischemia and reperfusion in rat hearts. J Cardiovasc Pharmacol. 1999;33:785-790.
279. Witherow FN, Helmy A, Webb DJ, Fox KA, Newby DE. Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Circulation. 2001;104:2177-2181.
280. Lagneux C, Adam A, Lamontagne D. A study of the mediators involved in the protection induced by exogenous kinins in the isolated rat heart. Int Immunopharmacol. 2003;3:1511-1518.
281. Emanueli C, Bonaria Salis M, Stacca T, Pintus G, Kirchmair R, Isner JM, et al. Targeting kinin B(1) receptor for therapeutic neovascularization. Circulation. 2002;105:360-366.
282. Aramori I, Zenkoh J, Morikawa N, O'Donnell N, Asano M, Nakamura K, et al. Novel subtype-selective nonpeptide bradykinin receptor antagonists FR167344 and FR173657. Mol Pharmacol. 1997;51:171-176.
283. Majima M, Hayashi I, Inamura N, Fujita T, Ogino M. A nonpeptide mimic of bradykinin blunts the development of hypertension in young spontaneously hypertensive rats. Hypertension. 2000;35:437-442.
284. Emerich DF, Dean RL, Osborn C, Bartus RT. The development of the bradykinin agonist labradimil as a means to increase the permeability of the blood-brain barrier: from concept to clinical evaluation. Clin Pharmacokinet. 2001;40:105-123.
285. Liesmaa I, Kuoppala A, Shiota N, Kokkonen JO, Kostner K, Mayranpaa M, et al. Increased expression of bradykinin type-1 receptors in endothelium of intramyocardial coronary vessels in human failing hearts. Am J Physiol Heart Circ Physiol. 2005;288:H2317-H2322.
286. Decarie A, Adam A, Couture R. Effects of captopril and Icatibant on bradykinin (BK) and des [Arg9] BK in carrageenan-induced edema. Peptides. 1996;17:1009-1015.
287. Cruwys SC, Garrett NE, Perkins MN, Blake DR, Kidd BL. The role of bradykinin B1 receptors in the maintenance of intra-articular plasma extravasation in chronic antigen-induced arthritis. Br J Pharmacol. 1994;113:940-944.
288. Pesquero JB, Araujo RC, Heppenstall PA, Stucky CL, Silva JA Jr, Walther T, et al. Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors. Proc Natl Acad Sci U S A. 2000;97:8140-8145.
289. Dray A, Patel IA, Perkins MN, Rueff A. Bradykinin-induced activation of nociceptors: receptor and mechanistic studies on the neonatal rat spinal cord-tail preparation in vitro. Br J Pharmacol. 1992;107:1129-1134.
290. Dray A. Kinins and their receptors in hyperalgesia. Can J Physiol Pharmacol. 1997;75:704-712.
291. Belichard P, Landry M, Faye P, Bachrarov DR, Bouthillier J, Druneau D, et al. Inflammatory hyperalgesia induced by zymosan in the plantar tissue of the rat: effect of kinin receptor antagonists. Immunopharmacology. 2000;46:139-147.
292. Burgess GM, Perkins MN, Rang HP, Campbell EA, Brown MC, McIntyre P, et al. Bradyzide, a potent non-peptide B(2) bradykinin receptor antagonist with long-lasting oral activity in animal models of inflammatory hyperalgesia. Br J Pharmacol. 2000;129:77-86.
293. Ma QP, Heavens R. Basal expression of bradykinin B1 receptor in the spinal cord in humans and rats. Neuroreport. 2001;12:2311-2314.
294. Wotherspoon G, Winter J. Bradykinin B1 receptor is constitutively expressed in the rat sensory nervous system. Neurosci Lett. 2000;294:175-178.
295. Shughrue PJ, Ky B, Austin CP. Localization of B1 bradykinin receptor mRNA in the primate brain and spinal cord: an in situ hybridization study. J Comp Neurol. 2003;465:372-384.
296. Ongali B, Campos MM, Petcu M, Rodi D, Cloutier F, Chabot JG, et al. Expression of kinin B1 receptors in the spinal cord of streptozotocin-diabetic rat. Neuroreport. 2004;15:2463-2466.
297. Zausinger S, Lumenta DB, Pruneau D, Schmid-Elsaesser R, Plesnila N, Baethmann A. Therapeutical efficacy of a novel non-peptide bradykinin B2 receptor antagonist on brain edema formation and ischemic tissue damage in focal cerebral ischemia. Acta Neurochir Suppl. 2003;86:205-207.
298. Zausinger S. Bradykinin receptor antagonists in cerebral ischemia and trauma. IDrugs. 2003;6:970-975.
299. Prat A, Biernacki K, Pouly S, Nalbantoglu J, Couture R, Antel JP. Kinin B1 receptor expression and function on human brain endothelial cells. J Neuropathol Exp Neurol. 2000;59:896-906.
300. Prat A, Weinrib L, Becher B, Poirier J, Duquette P, Couture R, et al. Bradykinin B1 receptor expression and function on T lymphocytes in active multiple sclerosis. Neurology. 1999;53:2087-2092.
301. Bregola G, Varani K, Gessi S, Beani L, Bianchi C, Borea PA, et al. Changes in hippocampal and cortical B1 bradykinin receptor biological activity in two experimental models of epilepsy. Neuroscience. 1999;92:1043-1049.
302. Jaggar SI, Habib S, Rice AS. The modulatory effects of bradykinin B1 and B2 receptor antagonists upon viscero-visceral hyper-reflexia in a rat model of visceral hyperalgesia. Pain. 1998;75:169-176.
303. Stadnicki A, Pastucha E, Nowaczyk G, Mazurek U, Plewka D, Machinik G, et al. Immunolocalization and expression of kinin B1R and B2R receptors in human inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2005;289:G361-G366.
304. Gabra BH, Sirois P. Kinin B1 receptor antagonists inhibit diabetes-induced hyperalgesia in mice. Neuropeptides. 2003;37:36-44.
305. Gabra BH, Sirois P. Beneficial effect of chronic treatment with the selective bradykinin B1 receptor antagonists, R-715 and R-954, in attenuating streptozotocin-diabetic thermal hyperalgesia in mice. Peptides. 2003;24:1131-1139.
306. Zuccollo A, Navarro M, Frontera M, Cueva F, Carattino M, Catanzaro OL. The involvement of kallikrein-kinin system in diabetes type I (insulitis). Immunopharmacology. 1999;45:69-74.
307. Cloutier F, Couture R. Pharmacological characterization of the cardiovascular responses elicited by kinin B(1) and B(2) receptor agonists in the spinal cord of streptozotocin-diabetic rats. Br J Pharmacol. 2000;130:375-385.
308. Campos MM, Cabrini DA, Cardozo AH, Rae GA, Toro JH, Calixto JB. Changes in paw oedema triggered via bradykinin B(1) and B(2) receptors in streptozotocin-diabetic rats. Eur J Pharmacol. 2001;416:169-177.
309. Gabra BH, Sirois P. Role of bradykinin B(1) receptors in diabetes-induced hyperalgesia in streptozotocin-treated mice. Eur J Pharmacol. 2002;457:115-124.
310. Wang CH, Leung N, Lapointe N, Szeto L, Uffelman KD, Giacca A, et al. Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme Inhibitor, and angiotensin II type I receptor blocker. Circulation. 2003;107:1923-1929.
311. Shiuchi T, Nakagami H, Iwai M, Takeda Y, Cui T, Chen R, et al. Involvement of bradykinin and nitric oxide in leptin-mediated glucose uptake in skeletal muscle. Endocrinology. 2001;142:608-612.
312. Alfie ME, Sigmon DH, Pomposiello SI, Carretero OA. Effect of high salt intake in mutant mice lacking bradykinin-B2 receptors. Hypertension. 1997;29:483-487.
313. Margolius HS. Theodore Cooper Memorial Lecture. Kallikreins and kinins. Some unanswered questions about system characteristics and roles in human disease. Hypertension. 1995;26:221-229.
314. Couture R, Girolami JP. Putative roles of kinin receptors in the therapeutic effects of angiotensin 1-converting enzyme inhibitors in diabetes mellitus. Eur J Pharmacol. 2004;500:467-485.
315. Regoli D, Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol Rev. 1980;32:1-46.
316. Berkin KE. Respiratory effects of angiotensin converting enzyme inhibition. Eur Respir J. 1989;2:198-201.
317. Levy D, Zochodne DW. Increased mRNA expression of the B1 and B2 bradykinin receptors and antinociceptive effects of their antagonists in an animal model of neuropathic pain. Pain. 2000;86:265-271.
318. Drapeau G, Audet R, Levesque L, Godin D, Marceau F. Development and in vivo evaluation of metabolically resistant antagonists of B1 receptors for kinins. J Pharmacol Exp Ther. 1993;266:192-199.
319. Eric J, Gabra BH, Sirois P. Implication of the bradykinin receptors in antigen-induced pulmonary inflammation in mice. Br J Pharmacol. 2003;138:1589-1597.
320. Gera L, Stewart JM, Whalley ET, Burkard M, Zuzack JS. New bradykinin antagonists having very high potency at B1 receptors. Immunopharmacology. 1996;33:183-185.
321. Rhaleb NE, Gobeil F, Regoli D. Non-selectivity of new bradykinin antagonists for B1 receptors. Life Sci. 1992;51:PL125-PL129.
322. Burkard M, Zuzack JS, Jones S, Francis M, Whalley ET, Stewart JM, et al. Comparative profile of novel potent bradykinin antagonists at human B1 and B2 receptors. Immunopharmacology. 1996;33:186-190.
323. Gama Landgraf R, Jancar S, Steil AA, Sirois P. Modulation of allergic and immune complex-induced lung inflammation by bradykinin receptor antagonists. Inflamm Res. 2004;53:78-83.
324. Christiansen SC, Eddleston J, Woessner KM, Chambers SS, Ye R, Pan ZK, et al. Up-regulation of functional kinin B1 receptors in allergic airway inflammation. J Immunol. 2002;169:2054-2060.
325. Austin CE, Foreman JC. A study of the action of bradykinin and bradykinin analogues in the human nasal airway. J Physiol (Lond). 1994;478:351-356.
326. Asano M, Hatori C, Inamura N, Sawai H, Hirosumi J, Fujiwara T, et al. Effects of a nonpeptide bradykinin B2 receptor antagonist, FR167344, on different in vivo animal models of inflammation. Br J Pharmacol. 1997;122:1436-1440.
327. Abe Y, Kayakiri H, Satoh S, Inoue T, Sawada Y, Inamura N, et al. A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 2. Overcoming the species difference between guinea pig and man. J Med Chem. 1998;41:4053-4061.
328. Youngman MA, Carson JR, Lee JS, Dax SL, Zhang SP, Colburn RW, et al. Synthesis and structure - activity relationships of aroylpyrrole alkylamide bradykinin (B2) antagonists. Bioorg Med Chem Lett. 2003;13:1341-1344.
329. Lam YKT, Hensens OD, Ransom R, Giacobbe RA, Polishook J, Zink D. L-755,807, A New Non-Peptide Bradykinin Binding Inhibitor From An Endophytic Microsphaeropsis Sp. Tetrahedron. 1996;52:1481-1486.